by Dale Harrison | Sep 14, 2022 | Press Releases
SAN ANTONIO–(BUSINESS WIRE)– bioAffinity Technologies, (NASDAQ: BIAF, BIAFW), a biotechnology company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, today announced publication of its research in...
by Dale Harrison | Sep 9, 2022 | Articles, News
San Antonio biotech goes public raising nearly $8M SEPTEMBER 9, 2022 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal Roughly eight years after its launch, San Antonio-based biotech bioAffinity...
by Dale Harrison | Sep 9, 2022 | Events
September 11-14, 2022 bioAffinity Technologies Presents its CyPath® Lung test and Exhibits at the National Association of Veterans’ Research and Education Foundation (NAVREF) President and Chief Executive Officer Maria Zannes will speak about bioAffinity Technologies...
by Maria Zannes | Sep 6, 2022 | Press Releases
San Antonio, TX – September 6, 2022 – bioAffinity Technologies, Inc. (“bioAffinity” or the “Company”) (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, and is researching...
by Maria Zannes | Sep 1, 2022 | Press Releases
SEPTEMBER 1, 2022(SAN ANTONIO, TX) bioAffinity Technologies, Inc., a cancer diagnostics company that develops non-invasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that...
